No slight whatsoever intended on Dr. Kelly's credentials.
If Dr. Kelly were a virologist/immunologist specializing in HIV or an oncologist, then the rationale for the move would be more obvious to me.
For now, I am just interested to see how this is (or is spun as) as a positive for CYDY.
When the quality of management (not the drug/science) is the main question mark/unknown in an investment (which it is for me), it's concerning to see continued shake-ups.
Still very positive and VERY long here. Just need this 'splained to me, as I said at first. GLTU.
News 
Market Data 
Discover 
